Unexpected allergenic 11S globulin (Act d 12) and 2S albumin (Act d 13) from kiwi seeds as novel

masked relevant components in kiwifruit allergy by Sirvent, Sofia et al.
                             Elsevier Editorial System(tm) for Journal of Allergy and Clinical Immunology 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Unexpected allergenic 11S globulin (Act d 12) and 2S albumin (Act d 13) from kiwi seeds as novel 
masked relevant components in kiwifruit allergy  
 
Article Type: Original Article 
 
Section/Category: Food, Drug, and Insect Sting Allergy and Anaphylaxis 
 
Keywords: food allergy, kiwifruit allergy, kiwi seeds, allergen, 11S globulin, 2S albumin, Act d 12, Act d 
13, component-resolved diagnosis, cross-reactivity 
 
Corresponding Author: Mr. Oscar Palomares, PhD 
 
Corresponding Author's Institution: Universidad Complutense 
 
First Author: Sofia  Sirvent, PhD 
 
Order of Authors: Sofia  Sirvent, PhD; Belén Cantó, BSc; Javier Cuesta-Herranz, MD, PhD; Francisca 
Gómez, MD; Natalia Blanca, MD, PhD; Gabriela Canto, MD, PhD; Miguel Blanca, MD, PhD; Rosalía 
Rodríguez, PhD; Mayte Villalba, PhD; Oscar Palomares, PhD 
 
Manuscript Region of Origin: SPAIN 
 
Abstract: Background: Kiwifruit is a common cause of IgE-mediated food allergy. Component-resolved 
diagnosis of kiwifruit allergy suggests that relevant allergenic components are still undiscovered. The 
presence of allergens in kiwi seeds has not been investigated in detail so far. 
Objective: To increase the diagnostic sensitivity of kiwifruit allergy by identifying new allergens that 
might have been masked due to their specific location in seeds. 
Methods: Fifty-five kiwifruit allergic patients were included in the study. Immunoblotting, proteomic 
tools and Edman degradation were used to identify and purify IgE-reactive proteins from kiwi seeds. 
Circular dichroism, mass spectrometry, immunoblotting, enzyme-linked immunosorbent assay, skin 
prick test and IgE-inhibition experiments were used for structural and immunological characterization 
of purified allergens.  
Results: Two novel allergens, an 11S globulin (Act d 12) and a 2S albumin (Act d 13) have been 
identified and purified from kiwi seeds. Both purified molecules display the typical structural features 
reported for other members of their corresponding protein families. Act d 12 and Act d 13 retain IgE-
binding capacity and are recognized by 70.9 % and 18.2 %, respectively, of the tested kiwifruit allergic 
patients. Both purified allergens show in vivo allergenicity and display in vitro IgE-cross reactivity with 
homologous counterparts from peanut and tree nuts.  
Conclusion: The identification of 11S globulin Act d 12 and 2S albumin Act d 13 as novel relevant 
allergens from kiwi seeds and their availability as well-defined molecules might contribute to improve 
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ABSTRACT 33 
Background: Kiwifruit is a common cause of IgE-mediated food allergy. Component-34 
resolved diagnosis of kiwifruit allergy suggests that relevant allergenic components are still 35 
undiscovered. The presence of allergens in kiwi seeds has not been investigated in detail 36 
so far. 37 
Objective: To increase the diagnostic sensitivity of kiwifruit allergy by identifying new 38 
allergens that might have been masked due to their specific location in seeds. 39 
Methods: Fifty-five kiwifruit allergic patients were included in the study. Immunoblotting, 40 
proteomic tools and Edman degradation were used to identify and purify IgE-reactive 41 
proteins from kiwi seeds. Circular dichroism, mass spectrometry, immunoblotting, enzyme-42 
linked immunosorbent assay, skin prick test and IgE-inhibition experiments were used for 43 
structural and immunological characterization of purified allergens.  44 
Results: Two novel allergens, an 11S globulin (Act d 12) and a 2S albumin (Act d 13) 45 
have been identified and purified from kiwi seeds. Both purified molecules display the 46 
typical structural features reported for other members of their corresponding protein 47 
families. Act d 12 and Act d 13 retain IgE-binding capacity and are recognized by 70.9 % 48 
and 18.2 %, respectively, of the tested kiwifruit allergic patients. Both purified allergens 49 
show in vivo allergenicity and display in vitro IgE-cross reactivity with homologous 50 
counterparts from peanut and tree nuts.  51 
Conclusion: The identification of 11S globulin Act d 12 and 2S albumin Act d 13 as novel 52 
relevant allergens from kiwi seeds and their availability as well-defined molecules might 53 
contribute to improve the diagnosis of kiwifruit allergy. 54 
 55 
 56 
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CLINICAL IMPLICATIONS: Kiwi seeds are a source of relevant allergens for kiwifruit 57 
allergic patients. The inclusion of Act d 12 and Act d 13 in component-resolved diagnosis 58 
of kiwifruit allergy could reduce the number of misdiagnosed patients. 59 
 60 
CAPSULE SUMMARY: We have purified and characterized two novel relevant allergens 61 
from kiwi seeds (Act d 12 and Act d 13) previously overlooked in the context of kiwifruit 62 
allergy that might well contribute to improve the diagnostic sensitivity. 63 
 64 
KEY WORDS: food allergy, kiwifruit allergy, kiwi seeds, allergen, 11S globulin, 2S 65 
albumin, Act d 12, Act d 13, component-resolved diagnosis, cross-reactivity  66 
 67 
ABBREVIATIONS: 68 
CRD: Component-resolved diagnosis 69 
OAS: Oral allergy syndrome 70 
SPT: Skin prick test 71 
ELISA: Enzyme-linked immunosorbent assay 72 
OD: Optical density 73 
MS: Mass spectrometry  74 
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Introduction 75 
Kiwifruit (Actinidia deliciosa) is a common cause of IgE-mediated food allergy.1-3 The 76 
prevalence of kiwifruit allergy has significantly increased over the last years, being 77 
currently considered among the top 10 food allergies.4, 5 The main clinical manifestations 78 
triggered by kiwifruit ingestion range from mild local oral allergy syndrome (OAS), which is 79 
frequently associated to birch and grass pollen allergy,6 to severe systemic reactions 80 
including anaphylaxis which is mainly experienced by patients monosensitized to kiwifruit.7, 81 
8 Kiwifruit allergy has been also associated to latex allergy9, 10 and to occupational baker’s 82 
asthma.11 83 
The gold standard approach to accurately diagnose kiwifruit allergy remains 84 
double-blind placebo-controlled food challenges, but the main inconveniences to this 85 
approach include the difficulty to properly mask kiwifruit and the risk of anaphylactic 86 
reactions.12, 13 Different attempts at improving the in vivo and in vitro diagnosis of kiwifruit 87 
allergy have been performed.1-3, 5 Several studies demonstrated prick to prick test with 88 
fresh kiwifruit as a highly sensitive method for diagnosis of kiwifruit allergy (83 % to 100 %) 89 
with low specificity (around 31 %). In contrast, in vivo SPT and in vitro serum specific-IgE 90 
determinations with commercially available kiwifruit extracts improved specificity (40%-45 91 
%) but showed lower sensitivity (17 %-60 %) than prick to prick tests. Recent studies 92 
demonstrated component-resolved diagnosis (CRD) with purified natural and recombinant 93 
kiwifruit allergens as an alternative not only for increasing the diagnostic sensitivity but 94 
also to link specific IgE-sensitization patterns with clinical features.1, 2, 14  95 
Up to date, 11 kiwifruit allergens from distinct protein families and with different 96 
clinical relevance have been described according to the International Union of 97 
Immunological Societies (IUIS) allergen nomenclature subcommittee (www.allergen.org).1, 98 
5 These allergens include Act d 1 (Actinidin, a cysteine protease), Act d 2 (thaumatin-like 99 
protein), Act d 3 (40 kDa glycoallergen), Act d 4 (cystatin), Act d 5 (kiwellin), Act d 6 (pectin 100 
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methylesterase inhibitor), Act d 7 (pectin methylesterase), Act d 8 (Bet v 1 homologue 101 
protein), Act d 9 (profilin), Act d 10 (non-specific lipid transfer protein (nsLPT)) and Act d 102 
11 (major latex protein/ripening-related protein). The use of purified kiwifruit allergens in 103 
CDR approaches improved the diagnostic sensitivity up to 65% with respect to commercial 104 
kiwifruit extracts,1 but there are still a large number of kiwifruit allergic patients that did not 105 
show reactivity to any of the allergens included in that work, suggesting that other highly 106 
relevant allergenic proteins from kiwi might remain still undiscovered. At this regard, 107 
almost all the kiwifruit allergens described so far have been identified in the kiwi pulp and 108 
only Act d 10 (LTP) has been reported to be also contained in kiwi seeds.15 There are 109 
several key aspects that make plausible the existence of additional relevant allergens in 110 
kiwi seeds that might have been overcome in the context of kiwifruit allergy: i) kiwi seeds 111 
are not usually removed from the kiwifruit, and therefore, they are also ingested together 112 
with the kiwi pulp; ii) different seeds from other species are well-recognized potent 113 
inducers of food allergy;16-19 iii) seeds contain high levels of very stable allergenic proteins 114 
such as 2S albumins, 7S vicilins or 11S globulins able to sensitize at the gastrointestinal 115 
level and involved in cross-reactivity.20-22 The aim of this study was to identify and 116 
characterize new relevant allergens specifically present in kiwi seeds that might help to 117 
improve the current diagnosis of kiwifruit allergy.  118 
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METHODS 119 
Patients allergic to kiwifruit 120 
Kiwifruit allergic patients were diagnosed following the criteria previously reported23 and 121 
recruited from the Allergy Service of 3 different centers in Spain: Hospital Carlos Haya 122 
from Málaga and Hospitals Fundación Jiménez Díaz and Infanta Leonor from Madrid. The 123 
study was approved by the Ethic Committee of the 3 Hospitals, and written informed 124 
consent was obtained from all subjects. During the patient consultation a questionnaire 125 
gathering relevant clinical information was filed out by an allergist and all the patients were 126 
tested by skin prick test (SPT) for a battery of foods (including kiwifruit) and aeroallergens 127 
commonly sensitizing in the Mediterranean area with commercial available extracts (ALK-128 
Abelló and LETI). Serum samples from all the patients were collected for specific IgE 129 
determinations and storage at -20ºC. Sera from non-atopic and pollen-allergic patients 130 
without food allergy were used as controls.  131 
Fully detailed Methods on the preparation of home-made kiwi extracts (total, pulp 132 
and seeds), skin prick test, purification of Act d 12 and Act d 13, immunoblotting, ELISA, 133 
analytical, circular dichroism and proteomic procedures are described in the materials and 134 
methods section of the Online Repository.  135 
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RESULTS 136 
Clinical features of patients allergic to kiwifruit 137 
The general clinical characteristics of the 55 kiwifruit allergic patients included in this study 138 
are summarized in Table I. Median age of the patients was 34.8 yrs [25.0-42.0], with a 139 
predominance of females (39 vs 16). Thirty-four patients (61.8 %) referred exclusively local 140 
symptoms and 21 patients (38.2 %) developed immediate systemic reactions after the 141 
ingestion of kiwifruit. The most frequent reported symptom was OAS (61.8 %) and there 142 
were also 9 patients suffering from anaphylaxis (16.3 %). Other reported symptoms 143 
included angioedema (14.5 %), generalized urticaria (5.4 %), contact urticaria (3.6 %) and 144 
gastrointestinal disorders (1.8 %). Twelve patients (21.8 %) were only allergic to kiwifruit, 145 
tolerating the remaining plant-derived foods at the moment of the study. The other 43 146 
patients (78.2 %) suffered symptoms with other plant foods, being members of the 147 
Rosaceae family the most frequently reported allergies (28 patients) followed by the tree 148 
nuts (23 patients) and peanut (17 patients). Thirty-two patients (58.2 %) were also allergic 149 
to pollens. SPT to all the above mentioned food allergenic sources and the most common 150 
sensitizing food and pollens in the Mediterranean area24 were performed (data not shown). 151 
Only 28/55 patients included in this study (50.9 %) showed positive SPT with commercial 152 
kiwifruit extract. We grouped the kiwifruit allergic patients according to positive (group 1) or 153 
negative (group 2) SPT to kiwifruit extract (Table I). Only 14/28 patients from group 1 (50.0 154 
%) and 5/27 from group 2 (18.5 %) had IgE to kiwifruit extract by ELISA. 155 
 156 
Detection of IgE-reactive proteins in kiwi seeds  157 
We assayed two pools of sera from patients included in the group 1 and 2, respectively, 158 
against home-made total kiwifruit (pulp and seeds), pulp kiwifruit and kiwi seeds extracts in 159 
immunoblotting for detection of IgE-reactive proteins. The protein content of total and pulp 160 
kiwifruit extracts was very similar (lane CBS, Figure 1). Two main proteins bands of around 161 
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51 and 12 kDa were observed in kiwi seeds but not in total and pulp kiwifruit extracts (lane 162 
CBS, Figure 1). Both proteins were recognized by the two pools of sera (Figure 1), 163 
suggesting that these IgE-reactive proteins might represent two novel allergens from kiwi 164 
seeds. The pool of sera from group 2 (negative SPT to kiwifruit extract) exclusively reacted 165 
against the allergens contained in kiwi seeds extract, whereas the pool of sera from group 166 
1 (positive SPT to kiwifruit extract) also reacted to other proteins bands of around 20-22, 167 
27-30 and 36 kDa contained in total and pulp kiwifruit but not in kiwi seeds extract.  168 
We tested the sera from all the patients against kiwi seeds extract (Figure 2) and 169 
total kiwifruit extract (Figure E1). Thirty-nine out of the 55 patients (70.1 %) reacted to the 170 
protein of 51 kDa in kiwi seeds (Figure 2), 21/28 (75 %) and 18/27 (66.7 %) from groups 1 171 
and 2, respectively. Ten out of the 55 patients (18.2 %) showed positive response to the 172 
protein of 12 kDa in kiwi seeds, 4/28 (14.3 %) and 6/27 (22.2 %) from groups 1 and 2, 173 
respectively. Seven patients also reacted against an IgE-reactive protein of around 23 kDa 174 
in kiwi seeds. Twenty out of the 28 patients from group 1 (71.4 %) showed specific IgE to 175 
at least one allergen contained in total kiwifruit extract, whereas only 5/27 (18.5 %) from 176 
group 2 were positive (Figure E1). The same result was obtained for kiwifruit pulp extract 177 
(data not shown). The IgE-reactive proteins of 51 and 12 kDa in kiwi seeds extract were 178 
not contained in total nor pulp kiwifruit extract. 179 
 180 
Identification and structural characterization of two novel allergens in kiwi seeds: 181 
11S globulin (Act d 12) and 2S albumin (Act d 13)  182 
The IgE-reactive protein bands of 51 and 12 kDa contained in kiwi seeds were separated 183 
by SDS-PAGE (Figure 3A, inset), excised from the gel and digested with trypsin. The 184 
obtained peptides were analyzed by MALDI-TOF-MS and some of them (shaded arrows in 185 
MS-profile) subjected to fragmentation and MS/MS analysis. The identified peptides from 186 
each protein are indicated in the MS-profile (Figure 3A). The comparison of these peptides 187 
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with those from databases (Figure E2) allowed the identification of the proteins of 51 and 188 
12 kDa as an 11S globulin and a 2S albumin, respectively, which were named Act d 12 189 
(UniProt accession number C0HJF9) and Act d 13 (UniProt accession number C0HJG0) 190 
according to the IUIS allergen nomenclature subcommittee. 191 
Both allergens from kiwi seeds were purified to homogeneity (Figure 3B) following 192 
the sequential chromatographic steps described in the result section of the Online 193 
Repository (Figure E3). Edman degradation of the N-terminal of purified Act d 12 194 
rendered the double sequence, NRQPSKI and GLEETI. These sequences were 100 % 195 
and 83.3 % identical to those encompassed from residues 1 to 7 and 256 to 261, 196 
respectively, in the 11S globulin from Actinidia chinensis (UniProt accession A0EM47) 197 
(Figure E2A), which correspond to the N-terminal sequences of the large (32 kDa) and the 198 
small (20 kDa) subunits, respectively, of the allergen that are separated under reducing 199 
conditions (Figure 3B). The 2S albumin Act d 13 also consisted of two polypeptide chains 200 
of around 8 and 4 kDa disrupted by reducing agents (Figure 3B), but in this case we only 201 
obtained a single sequence, GPQQQHRL, by Edman degradation. This sequence showed 202 
63% identity with the N-terminal (positions 41 to 49) of the large chain of the 2S albumin 203 
Sin a 1 (UniProt accession P15322) (Figure E2B). MS of purified Act d 12 yielded a 204 
heterogeneous profile with two main peaks at 50207.3 and 52280.5 Da (Figure 3C), which 205 
might correspond to several isoforms as reported for other 11S globulin counterparts.25 For 206 
Act d 13 a single peak at 11359.0 Da was obtained (Figure 3C).  The circular dichroism 207 
(CD) spectra in the far-UV of purified Act d 12 and Act d 13 demonstrated that both 208 
allergens display a structured folding (Figure 3D). Temperature-dependent unfolding 209 
experiments (from 20ºC to 80 ºC) of Act d 12 and Act d 13 showed slight and reversible 210 
changes of secondary structure, indicating that both allergens are highly stable to thermal 211 
denaturation (Figure 3D). 212 
 213 
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IgE-binding capacity and in vivo allergenicity of Act d 12 and Act d 13 from kiwi 214 
seeds 215 
The IgE-binding capacity of purified Act d 12 and Act d 13 from kiwi seeds was assayed by 216 
ELISA and immunoblotting (Figure 4). Thirty-nine out of the 55 patients (70.1 %) were 217 
positive to purified Act d 12 in immunoblotting (21/28, 75.0 % from group 1 and 18/27, 66.7 218 
% from group 2) (Figure 4A), whereas 10/55 (18.2 %) were positive to Act d 13 in 219 
immunoblotting (4/28, 14.3 % from group 1 and 6/27, 22.2 % from group 2) (Figure 4B). 220 
Similar ELISA results were observed. Act d 12 was recognized in ELISA by 34/55 (63.6 %) 221 
of the patients (19/28 and 15/27, from groups 1 and 2, respectively) (Figure 4A). In 222 
contrast, Act d 13 was recognized by 14/55 (25.5 %) of the patients (4/28 and 10/27 from 223 
groups 1 and 2, respectively).  224 
The in vivo allergenic capacity of purified Act d 12 and Act d 13 from kiwi seeds 225 
was demonstrated in kiwifruit allergic patients by SPT (Figure 5). We tested by SPT 4 226 
kiwifruit allergic patients and 3 non-allergic subjects with kiwi seeds, purified Act d 12 and 227 
purified Act d 13 and compared the induced wheal areas (Figure 5A). Kiwifruit allergic 228 
patients but not healthy controls had positive SPT to kiwi seeds extract (4/4), purified Act d 229 
12 (4/4) and purified Act d 13 (3/4). Kiwifruit allergic patients and non-allergic subjects had 230 
comparable responses to histamine as positive control. A representative picture of the 231 
forearm from a kiwifruit allergic patient with positive SPT after challenge with the indicated 232 
allergens is shown in Figure 5B. 233 
 234 
Act d 12 and Act d 13 from kiwi seeds show in vitro IgE cross-reactivity with 235 
homologous counterparts from peanut and tree nuts 236 
Twenty-four out of the 55 patients included in this study (43.6 %) were also allergic to tree 237 
nuts or peanut and 22 out of these 24 patients (91.6 %) were sensitized to Act d 12 or Act 238 
d 13 (Table I and Figure 4). We performed in vitro IgE-inhibition experiments in 239 
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immunoblotting using purified Act d 12 and Act d 13 as well as allergenic extracts from kiwi 240 
seeds, peanut, almond, hazelnut and walnut. We pooled the sera from kiwifruit allergic 241 
patients sensitized to peanut and tree nuts into two groups (Table II): i) patients with 242 
specific IgE to Act d 12, and ii) patients with specific IgE to Act d 13. The IgE reactivity to 243 
the protein of 51 kDa in kiwi seeds extract was totally abolished when the pool of sera from 244 
patients sensitized to Act d 12 was preadsorbed to kiwi seeds extract or to the purified Act 245 
d 12 (Figure 6A). The IgE-binding to purified Act d 12 was significantly inhibited by peanut, 246 
almond, hazelnut and walnut (86%, 67%, 66% and 65%, respectively, as determined by 247 
scanning densitometry) and completely inhibited by kiwi seeds extract or purified Act d 12 248 
(Figure 6B). The IgE-reactivity to the protein of 12 kDa in kiwi seeds extract was also 249 
completely inhibited when the pool of sera from patients sensitized to Act d 13 was 250 
preadsorbed to kiwi seeds extract or to the purified Act d 13 (Figure 6C). The inhibition of 251 
the IgE-binding to the purified Act d 13 was observed when walnut (85%), peanut (70%) 252 
and almond (49%) but not hazelnut (10%) were employed as inhibitors (Figure 6D). 253 
Complete inhibition was obtained with kiwi seeds or the purified Act d 13.      254 
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DISCUSSION 255 
In this study, we uncovered two novel relevant allergens from kiwi seeds, an 11S globulin 256 
(Act d 12) and a 2S albumin (Act d 13) that might have been masked in the context of 257 
kiwifruit allergy due to their specific location in seeds. The identification of Act d 12 and Act 258 
d 13 from kiwi seeds and their possible availability as purified molecules might well 259 
contribute to improve the diagnostic sensitivity, which is currently one of the main 260 
drawbacks associated to kiwifruit allergy. Both allergens retained the capacity to bind 261 
serum IgE from kiwifruit allergic patients, being Act d 12 recognized by 70.9 % and Act d 262 
13 by 18.2 % of the patients included in this study. Act d 12 and Act d 13 showed in vivo 263 
allergenicity, as determined by SPT and displayed in vitro IgE-cross reactivity with 264 
homologous counterparts from peanut and tree nuts.  265 
Since the first case of kiwifruit allergy was reported in 1981,26 the prevalence of this 266 
IgE-mediated food allergy has enormously increased.1-4 Kiwifruit allergy is frequently 267 
associated to pollen or latex allergy with a wide range of clinical symptoms, which 268 
compounds accurate diagnosis.5 Diagnosis of kiwifruit allergy has significantly improved 269 
during the last years.1, 2, 5, 14 However, the main drawbacks are the low specificity for prick 270 
to prick tests, likely due to the analysis of dichotomized instead of the size of SPT 271 
outcomes,2-4 and the low sensitivity for in vivo SPT and in vitro serum specific-IgE 272 
determinations. Low sensitivity has been attributed to the lack of relevant allergens in 273 
commercial kiwifruit extracts3-5  and to the different content of allergenic proteins 274 
depending on the kiwi varieties.27-30 In this study, we included 55 patients with a suggestive 275 
clinical history of kiwifruit allergy reporting classical immediate IgE-mediated symptoms 276 
after ingestion of kiwifruit. Only 50.9 % of the patients showed positive SPT with 277 
commercial kiwifruit extract and 34.5 % of the patients were positive in ELISA, which is in 278 
accordance with the low sensitivity previously reported for such determinations.1, 5, 14 A 279 
recent study showed that the combination of purified kiwifruit allergens (Act d 1, 2, 5, 6, 9 y 280 
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10) improved the in vitro diagnostic sensitivity up to 65%.1 This study also suggested that 281 
35 % of kiwifruit allergic patients might be sensitized to undiscovered relevant allergens. 282 
Considering that all the currently known kiwifruit allergens, except Act d 10 (LTP),5, 15 have 283 
been exclusively described in the pulp of kiwifruit together with the fact that seeds are 284 
commonly ingested with the pulp, we hypothesized that novel key allergens in kiwi seeds 285 
might have been masked in the context of kiwifruit allergy.  286 
To identify novel allergens in kiwi seeds we grouped the patients according to 287 
positive or negative SPT to kiwifruit extract (groups 1 and 2, respectively) and tested the 288 
sera in immunoblotting with home-made kiwifruit extracts from total (pulp and seeds), pulp 289 
and seeds prepared following protocols previously described for each specific tissue (see 290 
Online Repository).31, 32 We detected two IgE-reactive protein bands of 50 and 12 kDa in 291 
kiwi seeds but not in total or pulp kiwifruit extracts, which were identified by proteomic tools 292 
and Edman degradation sequencing as an 11S globulin (Act d 12) and a 2S albumin (Act d 293 
13), respectively. These allergens from kiwi seeds were not detected in total and pulp 294 
kiwifruit extracts, likely due to the poor extraction of such proteins when using conventional 295 
protocols to prepare aqueous extracts from fruits.31, 32 The lack of kiwi seeds allergens in 296 
commercially available kiwifruit protein extracts might well justify why patients from group 2 297 
in this study did not show positive SPT. Around 85 % of the patients included in this study 298 
were positive to purified Act d 12 or Act d 13 from kiwi seeds, whereas only 45.5 % of the 299 
patients showed positive responses to total or pulp kiwifruit extracts in immunoblotting. 300 
The use of well-defined purified allergens is very useful to improve diagnosis and 301 
treatment of allergic diseases.33-35 The structural characterization of purified 11S globulin 302 
Act d 12 and 2S albumin Act d 13 demonstrated that both purified allergens display 303 
classical features of members from these protein families. 11S globulins and 2S albumins 304 
are very stable seed-specific storage proteins composed of two polypeptide chains linked 305 
by disulphide bridges that have been previously described as potent food allergens able to 306 
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induce primary sensitization at the gastrointestinal level and involved in IgE cross-307 
reactivity.21, 22, 31, 36-40 Act d 12 represents a major allergen recognized by 70.9 % of the 308 
kiwifruit allergic patients in this study. Five patients (# 20 and 25 from group 1 and 30, 42 309 
and 44 from group 2) that were positive to purified Act d 12 in immunoblotting did not react 310 
to the purified protein in ELISA, suggesting the existence of internal epitopes that are 311 
exposed after SDS-PAGE. Act d 13 is a minor allergen being recognized by 18.2% of the 312 
patients and 4 patients (# 30, 34, 41 and 42 from group 2) reacted to purified Act d 13 in 313 
ELISA but not in immunoblotting, suggesting the existence of potential conformational 314 
epitopes in the allergen that are altered under the denaturing conditions. Importantly, both 315 
native allergens demonstrated in vivo allergenicity as they were able to induce IgE 316 
crosslinking in effector skin mast cells when assayed in SPT. In vitro IgE-inhibition 317 
experiments demonstrated that purified Act d 12 and Act d 13 conserved common 318 
epitopes to homologous counterparts from peanut, almond, hazelnut or walnut, suggesting 319 
that Act d 12 and Act d 13 might be also involved in cross-reactivity with these allergenic 320 
sources. Although 91.6 % (22/24) of the kiwifruit allergic patients of this study that were 321 
also allergic to tree nuts or peanut were sensitized to Act d 12 or Act d 13 (15/24 to Act d 322 
12 and 9/24 to Act d 13), further detailed studies are required to elucidate the potential 323 
clinical relevance of this observed in vitro IgE-cross reactivity. 324 
Collectively, we identified and deeply characterized two novel relevant allergens 325 
from kiwi seeds. The inclusion of purified Act d 12 and Act d 13 in CRD might well 326 
contribute to significantly increase the diagnostic sensitivity of kiwifruit allergy, which might 327 
be especially relevant to properly diagnose those patients showing negative SPT with 328 
commercial kiwifruit extracts. Although our results indicate that Act d 12 and Act d 13 show 329 
in vitro IgE cross-reactivity with homologous counterparts from tree nuts and peanut, 330 
further detailed studies are required to firmly confirm the clinical relevance of this fact.  331 
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Table I. Clinical characteristics of patients with kiwifruit allergy  458 
GROUP 1: patients with  positive SPT to kiwifruit GROUP 2: patients with  negative SPT to kiwifruit 
Patient 
no. 
Sex/Age 
(y) 
Kiwifruit  
Symptoms 
Kiwifruit extract Other food  
allergies 
Pollen 
allergy 
Patient 
no. 
Sex/Age 
(y) 
Kiwifruit  
Symptoms 
Kiwifruit extract Other food  
allergies 
Pollen 
allergy SPT* ELISA† SPT* ELISA† 
1 F/32 AE 22 0.199 r,m,f,tr Yes 29 F/29 OAS Neg 0.051 s No 
2 M/27 U 22 0.146 r,n,p Yes 30 M/30 AE Neg 0.109 No Yes 
3 F/23 AE 44 0.075 r,pn,w,av,tr,b,t Yes 31 F/25 CU Neg 0.108 pt No 
4 M/47 OAS 22 0.056 m,pn No 32 F/46 OAS Neg 0.084 tr No 
5 F/32 U/OAS 22 0.808 No Yes 33 M/20 OAS Neg 0.067 No No 
6 M/48 AN 44 0.140 No Yes 34 F/32 AN Neg 0.075 No No 
7 F/25 AN 22 0.058 r,m No 35 M/17 CU Neg 0.085 n Yes 
8 F/42 OAS 22 0.064 r Yes 36 F/25 OAS Neg 0.088 n,b,pn Yes 
9 F/18 AE/OAS 22 0.115 n No 37 F/53 AE Neg 0.092 gr,p No 
10 M/21 AN 44 0.177 r,m,pn No 38 F/75 OAS Neg 0.105 r No 
11 M/77 OAS 22 0.113 No No 39 F/36 OAS Neg 0.112 r,n,p,tr No 
12 M/19 OAS 12 0.075 n,b,gr,p No 40 F/33 OAS Neg 0.079 r,n,p,t,s Yes 
13 F/26 OAS 22 0.068 r,n,t,p Yes 41 M/33 OAS Neg 0.080 r Yes 
14 M/51 GD 12 0.154 n,p No 42 F/50 AN Neg 0.081 No Yes 
15 F/20 OAS 12 0.063 r,n,p Yes 43 M/37 OAS Neg 0.235 r,n,p,m,f Yes 
16 M/30 AN 9 0.086 No Yes 44 F/37 OAS Neg 0.001 r,b,m,t,f,pn,tr No 
17 F/46 OAS 16 0.086 r,n,p,m,f,t,w No 45 F/35 OAS Neg 0.009 r,pn,t Yes 
18 M/19 AE 30 0.441 r,n,p,b,m,w,pn,f,gr Yes 46 F/75 OAS Neg 0.006 m,pn,gr,f No 
19 F/16 AE 16 0.171 r,n,tr,pn Yes 47 F/21 OAS Neg 0.020 r,n,p,b,t,pn,gr Yes 
20 F/43 OAS 40 0.824 r,n Yes 48 F/53 OAS Neg 0.013 r,m,pn,gr,tr Yes 
21 F/26 AN 25 0.376 No No 49 F/28 OAS Neg 0.020 n,av,m,pn Yes 
22 M/39 U 12 0.069 r,n,p Yes 50 F/29 OAS Neg 0.009 av,m,w,tr Yes 
23 F/34 AE 16 0.056 r,n,p,m,w,tr No 51 F/24 OAS Neg 0.007 r,b,m,pn Yes 
24 F/19 OAS 9 0.066 r,n,p Yes 52 F/72 OAS Neg 0.000 r,pn,tr,gr Yes 
25 M/36 AN 35 0.110 r,n,p,m,w,tr,av,gr,s Yes 53 F/34 OAS Neg 0.173 No No 
26 F/31 AN 35 0.226 No No 54 F/39 OAS Neg 0.142 n,p Yes 
27 F/34 OAS 16 0.118 No Yes 55 F/32 OAS Neg 0.219 r No 
28 F/17 OAS 12 0.212 r,n Yes        
y: year; M/F: male/female;  Neg: negative; AE: angioedema; AN: anaphylaxia; CU: contact urticaria; GD: gastrointestinal disorders; OAS: oral allergy syndrome;  
U: urticaria; av: avocado; b: banana; f: fig; gr: grape; m: melon; n: tree nuts including almond;  p: peanut; pn: pineapple; pt: potato; r: rosaceae excluding almond; s: soy;  
t: tomato; tr: tropical; w: watermelon; 
* Skin prick test wheal area in mm
2
 
†Specific IgE determined in ELISA as OD at 492 nm 
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Table II. Clinical features of the patients selected for in vitro IgE inhibition experiments  
Sera  
pool 
Patient  
number 
Kiwi  
symptoms 
Tree nuts*  
symptoms 
SPT (mm
2
) 
Kiwi Peanut Almond Hazelnut Walnut 
A
c
t 
d
 1
2
  
p
o
s
it
iv
e
 
13 OAS OAS 22 12 12 12 Neg 
22 U A, AN 12 12 Neg 48 Neg 
24 OAS OAS 9 9 20 12 9 
47 OAS OAS Neg 18 35 15 42 
54 OAS OAS Neg ND ND ND ND 
A
c
t 
d
 1
3
  
p
o
s
it
iv
e
 
2 U OAS 22 Neg Neg 22 Neg 
15 OAS OAS 12 12 Neg 10 12 
28 OAS OAS 12 ND ND ND ND 
39 OAS OAS Neg 12 Neg  22 22 
43 OAS AN, OAS Neg 22 22 22 Neg  
Neg: negative; A: asthma; AE: angioedema; AN: anaphylaxis; OAS: oral allergy syndrome; U: Urticaria; ND: not done 
*including almond 
  459 
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LEGEND TO FIGURES 460 
FIG 1. SDS-PAGE for total kiwi (left), kiwi pulp (middle) and kiwi seeds (right) extracts and 461 
Coomassie Blue staining (CBS) or IgE reactivity of sera from patients allergic to kiwi 462 
(group 1, patients with positive SPT to kiwi extract) and (group 2, patients with negative 463 
SPT to kiwi extract).  464 
FIG 2. IgE-reactivity of sera from patients allergic to kiwifruit of group 1 and 2 (lanes 1 to 465 
55) to kiwi seeds extract. C1 and C2 are sera from non-atopic and pollen allergic subjects, 466 
respectively. 467 
FIG 3. Identification and structural characterization of purified 11S globulin (Act d 12) and 468 
2S albumin (Act d 13). (A) MS-profile of the indicated proteins. Inset, SDS-PAGE of kiwi 469 
seeds extract stained with Coomassie blue staining (CBS) to visualized the excised bands 470 
(indicated arrows). Identified peptides are shown. The shadow arrows indicate the 471 
peptides identified by MS/MS analysis. (B) SDS-PAGE and CBS of kiwi seeds extract, 472 
purified Act d 12 and purified Act d 13 in the absence or presence of the reducing agent, β-473 
mercaptoethanol (me). (C) Molecular mass determination of the purified Act d 12 and Act 474 
d 13 by MS. (D) CD spectra of purified Act d 12 and Act d 13 in the far-UV at 20 ºC, at 85º 475 
C and cooling down again at 20 °C. Secondary structure contributions (α H, α-helix; β S, β-476 
sheet; β T, β-turn; RC, random coil) are shown. 477 
FIG 4. IgE-reactivity of purified Act d 12 (A) and Act d 13 (B). ELISA (upper panel) and 478 
immunoblotting (lower panel) are shown for the sera of the 55 patients allergic to kiwifruit 479 
grouped into patients with positive or negative SPT to kiwifruit extract. OD, optical density. 480 
C1 and C2, sera from non-atopic and pollen allergic subject, respectively.  481 
FIG 5. (A) Induced wheal size in kiwifruit allergic patients (A) and non-allergic controls 482 
(NA) by SPT with kiwi seeds extract, purified Act d 12, purified Act d 13 and histamine 483 
(positive control). Horizontal discontinuous line shows the cut off for negative (PBS) 484 
controls. Each symbol represents a single patient or healthy subject (B) Representative 485 
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example of the forearm of a kiwifruit allergic patient with positive SPT to the indicated 486 
allergens. 487 
FIG 6. Immunoblotting inhibition experiments. Inhibition of the IgE-binding to Act d 12 488 
contained in kiwi seeds extract (A) or to purified Act d 12 (B) by the indicated inhibitors 489 
when using a pool of sera from kiwifruit allergic patients sensitized to Act d 12. Inhibition of 490 
the IgE-binding to Act d 13 contained in kiwi seeds extract (C) or to purified Act d 13 (D) by 491 
the indicated inhibitors when using a pool of sera from kiwifruit allergic patients sensitized 492 
to Act d 13. BSA was used as negative control of inhibition. Percentages of inhibition are 493 
shown at the bottom of the figures (B) and (D). 494 
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MATERIALS and METHODS 29 
 30 
Preparation of home-made kiwi extracts (total, pulp and seeds)  31 
Kiwi seeds extract was obtained as previously described for yellow mustard seeds1 with 32 
minor modifications. Briefly, kiwi seeds were manually separated from the pulp of kiwifruit 33 
(Actinidia deliciosa) and lyophilized. Powder of kiwi seeds was suspended in 0.15 M 34 
sodium borate buffer, pH 8.0, at a 10% (wt/vol) ratio and gently stirred for 1 hour. After 35 
centrifugation at 4°C, the supernatant was collected and the pellet was reextracted twice 36 
with the same buffer and conditions. Collected supernatants were lyophilized. The 37 
resulting material was then extracted 3 times with 10% (wt/vol) acetone to remove lipid 38 
components. The obtained pellets containing extracted proteins were air desiccated and 39 
dissolved in 0.15 M ammonium bicarbonate, pH 8. After centrifugation at 8,500 rpm, at 40 
4°C, supernatants were lyophilized, quantified by Lowry method2 and stored at –20°C until 41 
used. Protein extracts for almond, hazelnut, peanut and walnut were prepared following 42 
the same protocol. 43 
Total (pulp and seed) or only pulp Kiwifruit extracts were prepared using as starting 44 
material peeled kiwifruit that were homogenized in 10% (wt/vol) ammonium bicarbonate 50 45 
mM and PMSF 1 mM in a blender. After 1 h mixing at 4 ºC, the homogenate was 46 
centrifuged for 30 min at 8,500 rpm at 4 ºC. The pellet was extracted again using the same 47 
solvent and the supernatants were collected, lyophilized and stored at -20 ºC until used. 48 
The lyophilized protein extracts were resuspended in 0.15 M ammonium bicarbonate, pH 49 
8.0 and quantified by Lowry method.2  50 
 51 
Skin prick tests  52 
SPT were performed in all patients according to standard procedures.3 The panel of 53 
commercial food and pollen extracts included the most relevant allergenic sources in the 54 
Mediterranean area. SPT with home-made kiwi seeds extract (100 g/mL) and with 55 
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purified natural Act d 12 (20 g/mL) and Act d 13 (20 μg/mL) were performed. Histamine 56 
dihydrochloride (10 mg/mL) and physiologic saline solutions were used as the positive and 57 
negative controls, respectively. Results of SPT were expressed as median wheal size in 58 
mm2 and a wheal diameter <7 mm2 was considered as negative.  59 
 60 
Purification of 11S globulin Act d 12 and 2S albumin Act d 13 61 
Lyophilized kiwi seed extract was dissolved in 0.15 M ammonium bicarbonate, pH 8.0, and 62 
applied onto a Sephadex G-50 column. Fractions containing protein bands of around 51 63 
and 12 kDa were separately pooled in Batch 1 and Batch 2, respectively. The batch 1 64 
containing the 11S globulin Act d 12 of around 51 kDa was further subjected to ion-65 
exchange chromatography on a DEAE-Cellulose column equilibrated in 20 mM ammonium 66 
bicarbonate buffer, pH 8.0. Proteins were eluted with a gradient from 20 to 500 mM 67 
ammonium bicarbonate buffer, pH 8.0 and visualized by Coomassie blue staining (CBS) 68 
after SDS-PAGE. The fractions containing the 11S globulin Act d 12 were pooled together. 69 
The batch 2 containing the 2S albumin Act d 13 of around 12 kDa was resolved on a 70 
reverse-phase high-performance liquid chromatographic (RP-HPLC) nucleosil C-18 71 
column with a gradient (25%–45%) of acetonitrile in 0.1% trifluoracetic acid. SDS-PAGE 72 
and CBS were carried out for all purification steps. IgE reactivity of the Act d 12 and Act d 73 
13 was analyzed for each purification step by using a pool of sera from kiwifruit allergic 74 
patients diluted 1/3. 75 
 76 
Immunoblotting 77 
Immunodetection of allergenic proteins after SDS-PAGE was performed with serum from 78 
patients allergic to kiwifruit (diluted 1/3) as described.4 The binding of human IgE was 79 
detected by mouse anti-human IgE antibodies (diluted 1:5000; ALK-Abelló), followed by 80 
horseradish peroxidase-labelled goat anti-mouse IgG (diluted 1:5000; Pierce). The signal 81 
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was developed with the ECL-Western blotting reagent (Amersham). For IgE-inhibition 82 
experiments the pool of sera (1/3 diluted) was preadsorbed with 1 mg/mL of peanut, 83 
almond, hazelnut and walnut protein extracts prepared as previously described for yellow 84 
mustard seeds1 or with 20 µg/mL of purified proteins overnight at 4ºC. BSA protein was 85 
used as negative control of inhibition. Volummograms of the reactive bands were analyzed 86 
by scanning densitometry using Multigauge software (Fujifilm). 87 
 88 
ELISA  89 
IgE quantitation was performed by ELISA in microtiter plates (Costar) coated with 100 90 
µl/well of purified proteins (2 µg/mL) or total kiwifruit extract (20 µg/mL).4 Plates were 91 
incubated with serum from kiwifruit allergic patients (dilution 1/3) and binding of IgE was 92 
detected as described above. Peroxidase reaction was developed using fresh enzyme 93 
substrate and measuring optical density (OD) at 492 nm. Each value was calculated as the 94 
mean of 2 determinations after blank subtraction. OD values <0.1 were considered 95 
negative responses. 96 
 97 
Analytical procedures  98 
SDS-PAGE was performed in 17 % polyacrylamide gels. Proteins were visualized by 99 
Coomassie blue staining (CBS) or alternatively transferred to nitrocellulose membranes 100 
(Amersham). The protein concentration was determined using the method of bicinchoninic 101 
acid (Pierce Chemical Co). 102 
Molecular mass determination of purified Act d 12 and Act d 13 was performed by 103 
mass spectrometry using a Bruker Reflex IV matrix-assisted laser-desorption ionization 104 
time-of-flight mass spectrometer (Bruker- Franzen Analytik), as described.5 The equipment 105 
was externally calibrated employing single-, double- and triple-charged signals from either 106 
cytocrome C (12,360 Da) or bovine serum albumin (66,430 Da).  107 
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N-terminal Edman degradation of purified Act d 12 and Act d 13 was performed 108 
using a 494 sequencer (Applied Biosystems-PE Corp.).  109 
 110 
Proteomic procedures 111 
Digestion, MS, and MS/MS analyses of the excised bands of around 51 and 12 kDa from 112 
the SDS-PAGE separations of kiwi seeds extract were carried out as previously 113 
described.1 The MS analyses were performed in a Voyager-DESTR instrument 114 
(PerSeptive Biosystems). All mass spectra were calibrated externally using a standard 115 
peptide mixture (Sigma-Aldrich). MS/MS sequencing analysis were carried out using the 116 
MALDI-tandem-TOF MS spectrometer 4700 Proteomics Analyzer (Applied Biosystems).  117 
 118 
Circular Dichroism 119 
The CD spectra were obtained using a JASCO J-715 spectropolarimeter  (Japan 120 
Spectroscopic Co.) fitted with a 150 W xenon lamp and connected to a Nestlab RTE-111 121 
thermostabilizer bath, at 20 °C and 85 ºC, as described.6 Far-UV spectra (190−250 nm 122 
wavelength) were registered using optical-path cell of 0.1 cm. The protein concentration 123 
was 0.2 mg/mL in 20 mM ammonium bicarbonate, pH 8. Mean residue mass ellipticities 124 
were calculated based on 110 as the average molecular mass/residue and expressed in 125 
terms of θ (degree × cm2 × dmol−1). Final spectra were corrected by subtracting the 126 
corresponding baseline spectrum obtained for the buffer alone under identical conditions.   127 
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RESULTS 128 
Purification of 11S globulin Act d 12 and 2S albumin Act d 13 from kiwi seeds 129 
Lyophilized kiwifruit seeds protein extract was separated by size in a gel-filtration 130 
chromatography (Figure E3A). Fractions containing the proteins of around 51 kDa (11S 131 
globulin Act d 12) and 12 kDa (2S albumin Act d 13) were pooled and named as Batch 1 132 
and 2, respectively, according to CBS after SDS-PAGE (Figure E3A, inset). The 11S 133 
globulin Act d 12 from kiwi seeds contained in batch 1 was purified to homogeneity by ion-134 
exchange chromatography (Figure E3B). The purified Act d 12 was visualized as a single 135 
protein by CBS after SDS-PAGE under non-reducing conditions and retained its IgE-136 
binding capacity as demonstrated by immunoblotting using sera from kiwifruit allergic 137 
patients (Figure E3B, inset). The 2S albumin Act d 13 from kiwi seeds contained in batch 2 138 
was further purified by RP-HPLC. The purified Act d 13 was also visualized as a single 139 
monomer of around 12 kDa by CBS after SDS-PAGE under non-reducing conditions that 140 
retained the IgE-binding capability as demonstrated by immunoblotting with sera from 141 
kiwifruit allergic patients (Figure E3C, inset).  142 
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LEGEND TO FIGURES 162 
FIG E1. IgE-binding profile to home-made total kiwifruit extract of the 55 kiwifruit allergic 163 
patients from group 1 (lanes 1 to 28) and group 2 (lanes 29 to 55). C1 and C2 are non-164 
atopic and pollen allergic subjects, respectively. 165 
 166 
FIG E2. A. Amino acid sequence alignment of 11S globulin from Actinidia chinensis 167 
(UNIPROT accession number A0EM47) and the peptides of Act d 12 determined by 168 
Edman degradation (ED) and MS/MS. B. Amino acid sequence alignment of Sin a 1, 2S 169 
albumin from yellow mustard seeds (UNIPROT accession number P15322) and the 170 
peptides of Act d 13 determined by Edman degradation (ED) and MS/MS. Identical amino 171 
acids are colored in grey. 172 
 173 
FIG E3. (A) Elution profile of kiwi seeds extract after a size-exclusion chromatography. 174 
Two main proteins of around 51 and 12 kDa were separated into Batch 1 and 2 (shadow in 175 
grey). The kiwi seeds extract and the proteins of each batch were visualized by CBS after 176 
SDS-PAGE (inset). (B) Elution profile of Batch 1 after ion-exchange chromatography. 177 
Fractions containing the 11S globulin Act d 12 is shadowed in grey. Purified Act d 12 was 178 
visualized by CBS and its IgE-binding capacity was analyzed with sera from kiwifruit 179 
allergic patients (inset). (C) Elution profile of Batch 2 in RP-HPLC. Fractions containing the 180 
2S albumin Act d 13 is shadowed in grey. Purified Act d 13 was visualized by CBS and its 181 
IgE-binding capacity was analyzed with sera from kiwifruit allergic patients (inset). 182 
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